Non-myeloablative allogeneic hematopoietic stem cell transplantation.
OBJECTIVE
To review the literature related to nonmyeloablative stem cell transplantation (SCT), and the unique characteristics and patient population to which it applies.


METHODS
Research studies, research and clinical reviews, clinical experience.


CONCLUSIONS
Nonmyeloablative SCT has demonstrated effective and safe application in a heterogeneous population not otherwise eligible for an allogeneic transplantation. Although many principles are based on those of conventional myeloablative transplantation, the engraftment kinetics, patient selection, and regimen-related complications are distinct.


CONCLUSIONS
Nurses must be knowledgeable about nonmyeloablative SCT, including the provision of individualized care for a heterogeneous population. This can include non-traditional transplant indications, elderly cancer patients, and those with comorbidities.
National Institutes of Health, Clinical Center, Department of Nursing and Patient Care Services, Bethesda, MD, USA. nshelburne@cc.nih.gov
Nonniekaye
N
Shelburne
Margaret
M
Bevans
D016465:Bone Marrow Purging / Q000009:adverse effects; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D009859:Oncology Nursing; D018579:Patient Selection; D012449:Safety; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D014184:Transplantation, Homologous / Q000009:adverse effects / Q000379:methods*; D016896:Treatment Outcome